IR820-PTX manufacturers
- IR820-PTX
-
- $176.00
-
2026-08-08
- CAS:2250419-19-1
- Purity: 98.15%
- Supply Ability: 10g
|
| | IR820-PTX Basic information |
| Product Name: | IR820-PTX | | Synonyms: | IR820-PTX;1H-Benz[e]indolium, 2-[2-[2-[[6-[(1R,2S)-2-(benzoylamino)-1-[[[(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl]oxy]carbonyl]-2-phenylethoxy]-6-oxohexyl]amino]-3-[2-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e]indol-2-ylidene]ethylidene]-1-cyclohexen-1-yl]ethenyl]-1,1-dimethyl-3-(4-sulfobutyl)-, inner salt, sodium salt (1:1) | | CAS: | 2250419-19-1 | | MF: | C99H112N4O21S2.Na | | MW: | 1781.09 | | EINECS: | | | Product Categories: | | | Mol File: | 2250419-19-1.mol |  |
| | IR820-PTX Chemical Properties |
| | IR820-PTX Usage And Synthesis |
| Uses | IR820-PTX, an IR-820 (HY-136886)-Paclitaxel (HY-B0015) conjugate, is an amphipathic small molecule prodrug. IR820-PTX effectively inhibits tumor growth via combined photothermal therapy (PTT) and chemotherapy[1][2]. | | References | [1] Zhang D, et al. pH- and Enzyme-Sensitive IR820-Paclitaxel Conjugate Self-Assembled Nanovehicles for Near-Infrared Fluorescence Imaging-Guided Chemo-Photothermal Therapy. ACS Appl Mater Interfaces. 2018 Sep 12;10(36):30092-30102. DOI:10.1021/acsami.8b09098 [2] Yu-Xia Luan, et al. Preparation method and application of amphiphilic small molecule prodrug of ir820-ptx combined with photothermal therapy and chemotherapy and its nanoparticles. CN108727353B. |
| | IR820-PTX Preparation Products And Raw materials |
|